Anthem Biosciences Lists At 27% Premium Over IPO Price

Anthem Biosciences Ltd. shares listed at Rs 723.05 apiece on the NSE and Rs 723.1 on the BSE.

Anthem Biosciences IPO received a solid response, particularly from Qualified Institutional Buyers. (Image: BSE livestream)

Quick Read
Summary is AI Generated. Newsroom Reviewed

  • Anthem Biosciences Ltd debuted in the secondary market with a 27% premium over its IPO price
  • The shares were listed at Rs 723.05 on the NSE
  • The shares were listed at Rs 723.1 on the BSE

Anthem Biosciences Ltd. made a stellar debut in the secondary market with a premium of 27% over its IPO price. The scrip was listed at Rs 723.05 apiece on the NSE and Rs 723.1 on the BSE. The issue price was Rs 570.

The IPO was a book-building issue of Rs 3,395 crore and entirely an offer for sale from its promoters, investors and other selling shareholders.

Since this IPO was fully an OFS, the contract research, development and manufacturing company will not receive any funds, which will be directed to the selling shareholders.

Anthem Biosciences IPO received a solid response, particularly from Qualified Institutional Buyers (QIBs) who subscribed 182.65 times, followed by non-institutional investors (NIIs) at 42.36 times.

Retail investors' quota had a subscription rate of 5.64 times. By the end of the third day, the Anthem Biosciences IPO subscription status stood at 63.86 times.

The initial share sale received bids for 281 crore shares against 4.4 crore shares on offer.

JM Financial was the sole domestic merchant banker to the deal.

Also Read: NLC India Arm NIRL To Launch Rs 4,000 Crore IPO In Q2 FY27

Anthem Biosciences is an innovation-driven and technology-focused contract research, development, and manufacturing organisation (CRDMO) with integrated operations encompassing drug discovery, development, and manufacturing processes.

The company serves customers, including emerging biotech firms and large pharmaceutical companies on a global scale. It manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.

Listed peers of Anthem Biosciences include Sai Life Sciences Ltd, Syngene International Ltd., Suven Life Sciences Ltd., and Divi’s Laboratories Ltd.

Also Read: Brigade Hotel Ventures IPO: Price Range Set For Rs 760 Crore — Check Details

Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.
WRITTEN BY
Shubhayan Bhattacharya
Shubhayan covers markets and business news at NDTV Profit. He has a keen in... more
GET REGULAR UPDATES